Amedisys Inc

Health Care
Medical/Nursing Services
www.amedisys.com

Earnings Score
Moat Score
Safety Score

Market Cap $2.80B
PE 34
Debt $421.20M
Cash $245.45M
EV $2.97B
FCF $204.37M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$82.63M
EBIT	$148.17M
ROE	7%
ROA	7%
FCF	$204.37M
Equity	$1.20B
Growth Stability	-6%
PE	33.86
PEG	-1.19
PB	2.33
P/FCF	13.69
P/S	1.21
Price/Cash	0.09
Debt/Equity	0.35
Debt/FCF	2.06
Net Margins	4%
Gross Margins	44%
Op. Margins	6%
Earnings CAGR	1%
Sales Growth YoY	6%
Sales Growth QoQ	-1%
Sales CAGR	4%
FCF CAGR	8%
Equity CAGR	14%
Earnings Stability	0
Earnings Growth YoY	-34%
Earnings Growth QoQ	-48%

Earnings CAGR 5Y	-28%
Sales CAGR 5Y	3%
FCF CAGR 5Y	-18%
Equity CAGR 5Y	13%
Earnings CAGR 3Y	1%
Sales CAGR 3Y	1%
FCF CAGR 3Y	-10%
Equity CAGR 3Y	6%
Market Cap	$2.80B
Revenue	$2.32B
Assets	$2.14B
Total Debt	$421.20M
Cash	$245.45M
Shares Outstanding	32.71M
EV	2.97B
Earnings Score	6%
Moat Score	78%
Safety Score	63%
Final Score	49%
Working Capital	93.93M
Current Ratio	1.19
Gross Profit	$1.01B
Shares Growth 3y	0%
Equity Growth QoQ	2%
Equity Growth YoY	10%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment , and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

SEC Filings

Direct access to Amedisys Inc (AMED) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Amedisys Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Amedisys Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%

Stability 0%

loading chart...

Amedisys Inc Discounted Cash Flow

Fully customizable DCF calculator online for Amedisys Inc.

Years

Calculation mode

= $3.6B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$204M	$221M	$240M	$260M	$281M	$305M	$330M	$357M	$387M	$419M	$454M	$4.5B
DCF		$201M	$198M	$195M	$192M	$189M	$186M	$183M	$180M	$178M	$175M	$1.7B
Value	$3.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	3%	2%	7%	6%	9%	9%	5%	-0%	4%
ROA	-	2%	9%	11%	23%	15%	14%	15%	9%	8%	7%
ROE	-	-1%	8%	6%	25%	20%	23%	21%	11%	-1%	7%

Bad Net Margins (3.63%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	1.22	2.17	1.07	0.06	1.32	0.8	2.53	3.57	3.32	2.06
Debt over Equity	0.32	0.26	0.22	0.2	0.03	0.4	0.28	0.47	0.41	0.39	0.35
Growth Stability	-	-	-	100%	100%	100%	100%	100%	68%	-6%	-6%

Neutral Debt/FCF ratio (2.06)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.35)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-6%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	6%	10%	18%	6%	7%	0%	1%	3%
Earnings YoY growth	-	-124%	-1K%	-19%	294%	6%	45%	14%	-44%	-109%	-28%
Equity YoY growth	-	3%	12%	12%	-7%	33%	26%	20%	13%	1%	13%
FCF YoY growth	-	-211%	-46%	104%	128%	-11%	46%	-36%	-30%	4%	-18%